

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUNPHARMA

复星医药

上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

(1) CHANGE OF JOINT COMPANY SECRETARY AND

(2) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND

(3) APPOINTMENT OF CHAIRMAN OF SUPERVISORY COMMITTEE

(1) CHANGE OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Qiao Zhicheng (“**Mr. Qiao**”) has resigned as the joint company secretary of the Company (“**Joint Company Secretary**”) with effect from 28 June 2013.

Mr. Qiao confirmed that he had no disagreement with the Board and there were no other matters in respect of his resignation that need to be brought to the attention of the shareholders of the Company and the Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”).

The Board further announces that Mr. Zhou Biao (周颺) (“**Mr. Zhou**”) has been appointed as a Joint Company Secretary with effect from 28 June 2013.

Mr. Zhou, aged 42, joined the Group in June 2013, is currently a vice president, secretary and joint secretary to the Board of the Company. Prior to joining the Group, Mr. Zhou served as a lawyer of Shanghai Qiao Wen Law Firm (上海市喬文律師事務所) from September 1996 to May 2000 and a lawyer of Shanghai Hua Ye Law Firm (上海市華擘律師事務所) from May 2000 to May 2005. Mr. Zhou was a lawyer of Shanghai Jiu Cheng Law Firm (上海久誠律師事務所) from May 2005 to June 2013 and has provided legal service to the Company since then. Mr. Zhou obtained a bachelor of laws (majoring in economic law) from Fudan University (復旦大學) in July 1993.

Mr. Zhou currently does not possess the specified qualifications as required under Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the “**Hong Kong Listing Rules**”), but Mr. Zhou is knowledgeable and experienced in the operations of the Group. In this respect, the Company has applied for, and the Hong Kong Stock Exchange has granted a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Hong Kong Listing Rules in relation to Mr. Zhou’s eligibility to act as a joint company secretary for a three-year period starting from 28 June 2013, on the condition that, among other things, Mr. Zhou will be assisted by Ms. Lo Yee Har Susan (the current Joint Company Secretary) during the said period.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Qiao for his valuable contributions to the Company during his tenure of office and to extend our warm welcome to Mr. Zhou for his new appointment.

(2) APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that Mr. Yao Fang (姚方) (“**Mr. Yao**”) has been appointed as the chief executive officer of the Company (“**Chief Executive Officer**”) for a term of three years with effect from 28 June 2013.

The biographical details of Mr. Yao is as follows:

Positions and experience

Mr. Yao, aged 43, is the executive Director, vice Chairman and President (Chief Executive Officer) of the Company. Mr. Yao served as the deputy general manager and chief financial officer of the Company from April 2010 to June 2010, and as the vice Chairman and general manager of the Company from June 2010 to October 2012. He was an executive Director, vice chairman and President of the Company from October 2012 to June 2013, and has been an executive Director, vice Chairman and President (Chief Executive Officer) of the Company since June 2013. Prior to joining the Group, from 1993 to 2009, Mr. Yao was successively the assistant general manager of the international business department of Shanghai Wanguo Securities Company Limited, now known as Shenyin & Wanguo Securities Company Limited (申銀萬國證券股份有限公司), general manager of Shanghai Industrial Assets Management Company Limited (上海上實資產經營有限公司), general manager of Shanghai Industrial Management (Shanghai) Company Limited (上實管理(上海)有限公司), managing director of Shanghai Industrial Pharmaceutical Investment Company Limited (上海實業醫藥投資股份有限公司), a company delisted from the Shanghai Stock Exchange on 12 February 2010, chairman of Shanghai Overseas Company (上海海外公司), non-executive director of Lianhua Supermarket Holdings Company Limited (聯華超市股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 00980), and executive director of Shanghai Industrial Holdings Limited (上海實業控股有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 00363). Mr. Yao is currently a non-executive director of BioSino Bio-Technology and Science Incorporation (中生北控生物科技股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 08247), and chief supervisor of Sinopharm

Group Company Limited, a company listed on the Hong Kong Stock Exchange (stock code: 01099). Mr. Yao is a vice chairman of the Shanghai Pharmaceutical Industry Association (上海醫藥行業協會) since June 2010. Mr. Yao obtained a bachelor degree of economics from Fudan University (復旦大學) in July 1989 and a master degree of business administration from The Chinese University of Hong Kong in December 1993.

Save as disclosed above, Mr. Yao has not held other directorship in any public companies whose securities are listed on any securities market in Hong Kong or overseas in the past three years.

Term of service and remuneration

The Company appoints Mr. Yao as the Chief Executive Officer for a term of three years. Mr. Yao will not receive any remuneration from the Group as a Director and Chief Executive Officer, but will be remunerated as a senior management of the Company pursuant to the applicable remuneration policy of the senior management.

Relationship

As far as the Directors are aware, Mr. Yao does not have any relationship with other Directors, supervisors, senior management or substantial shareholders of the Company.

Interests in shares

To the knowledge of the Directors, as at the date of this announcement, Mr. Yao was not interested or deemed to be interested in shares within the meaning of Part XV of the Securities and Futures Ordinance.

Other information and matters that need to be disclosed or brought to the attention of the shareholders of the Company

To the knowledge of the Directors, there are no other matters regarding Mr. Yao that need to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Hong Kong Listing Rules nor is there any other information regarding Mr. Yao which needs to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Mr. Yao to assume his new position.

(3) APPOINTMENT OF THE CHAIRMAN OF THE SUPERVISORY COMMITTEE

The Board further announces that Mr. Zhou Wenyue (周文岳) has been elected by the supervisory committee of the Company (the “**Supervisory Committee**”) as the chairman of the sixth session of the Supervisory Committee for a term of three years with effect from 28 June 2013.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

Shanghai, the PRC

28 June 2013

As at the date of this announcement, the executive Directors are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive Directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Zhang Guozheng, Mr. Wang Pinliang and Ms. Kang Lan; and the independent non-executive Directors are Mr. Han Jiong, Dr. Zhang Weijiong, Mr. Li Man-kiu Adrian David and Mr. Cao Huimin.

* *for identification purposes only*